Testing single/combined clinical categories on 5110 Italian patients with developmental phenotypes to improve array-based detection rate.

A new interesting article has been published in Mol Genet Genomic Med. 2019 Dec 18:e1056. doi: 10.1002/mgg3.1056. and titled:

Testing single/combined clinical categories on 5110 Italian patients with developmental phenotypes to improve array-based detection rate.

Authors of this article are:

Catusi I, Recalcati MP, Bestetti I, Garzo M, Valtorta C, Alfonsi M, Alghisi A, Cappellani S, Casalone R, Caselli R, Ceccarini C, Ceglia C, Ciaschini AM, Coviello D0, Crosti F, D’Aprile A, Fabretto A, Genesio R, Giagnacovo M, Granata P, Longo I, Malacarne M0, Marseglia G, Montaldi A, Nardone AM, Palka C, Pecile V, Pessina C, Postorivo D, Redaelli S, Renieri A, Rigon C, Tiberi F, Tonelli M, Villa N, Zilio A, Zuccarello D, Novelli A0, Larizza L, Giardino D.

A summary of the article is shown below:

BACKGROUND: Chromosomal microarray analysis (CMA) is nowadays widely used in the diagnostic path of patients with clinical phenotypes. However, there is no ascertained evidence to date on how to assemble single/combined clinical categories of developmental phenotypic findings to improve the array-based detection rate.METHODS: The Italian Society of Human Genetics coordinated a retrospective study which included CMA results of 5,110 Italian patients referred to 17 genetics laboratories for variable combined clinical phenotypes.RESULTS: Non-polymorphic copy number variants (CNVs) were identified in 1512 patients (30%) and 615 (32%) present in 552 patients (11%) were classified as pathogenic. CNVs were analysed according to type, size, inheritance pattern, distribution among chromosomes, and association to known syndromes. In addition, the evaluation of the detection rate of clinical subgroups of patients allowed to associate dysmorphisms and/or congenital malformations combined with any other single clinical sign to an increased detection rate, whereas non-syndromic neurodevelopmental signs and non-syndromic congenital malformations to a decreased detection rate.CONCLUSIONS: Our retrospective study resulted in confirming the high detection rate of CMA and indicated new clinical markers useful to optimize their inclusion in the diagnostic and rehabilitative path of patients with developmental phenotypes.© 2019 The Authors. Molecular Genetics & Genomic Medicine published by Wiley Periodicals, Inc.

Check out the article’s website on Pubmed for more information:

This article is a good source of information and a good way to become familiar with topics such as: Chromosomal microarray analysis (CMA); clinical marker identification; detection rate; pathogenic CNV.

NativeFolder: The Only Bacterial Culture Medium for the Expression of Soluble Proteins

Interference Test Kit for Assay Validation

Rheumatoid Factor Interference Blocker

New Antibodies from MOLECULAR DEPOT

New Proteins from MOLECULAR DEPOT

New Chemicals from MOLECULAR DEPOT

Molecular Depot

Your specialty peptide, proteins, antibodies and chemical compounds store.